Supernus Pharmaceuticals, Inc. (SUPN) Market Cap & Valuation Ratios
Supernus Pharmaceuticals, Inc. (SUPN) has a market cap of $2.4B and a price-to-sales ratio of 2.9, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
SUPNSupernus Pharmaceuticals, Inc.Follow SUPN — free
—
Price chart with a free account
- Market cap
- 2.4B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Peers
drug manufacturers - specialty & generic · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| SUPN | 2.4 | — | 2.6 | — | 0.8% | +25% | -16% | -15% |
| LQDA | 3.8 | 31.2 | 8.2 | 21.8 | 3.9% | +2234% | 37% | 180% |
| RGC | 3.8 | — | — | — | — | — | — | — |
| AMLX | 3.0 | — | — | — | -4.2% | — | — | -108% |
| PBH | 2.3 | 13.4 | 3.8 | 13.0 | 10.4% | -1% | 26% | 6% |
| PRGO | 2.2 | — | 1.2 | — | 5.4% | -4% | -38% | -24% |
| TRLV | 2.0 | — | 1.7 | — | 9.3% | -4% | -24% | -27% |
| BCRX | 2.0 | — | 2.1 | — | 19.1% | +69% | -33% | — |
| XERS | 1.9 | — | 5.9 | 52.5 | 3.0% | +36% | 11% | 28% |
| ANIP | 1.7 | 15.7 | 2.0 | 8.1 | 10.4% | +31% | 15% | 13% |
| PAHC | 1.6 | 15.9 | 1.5 | 9.1 | 0.6% | +17% | 13% | 14% |
| Median of these 10 | 15.8 | 2.0 | 13.0 | 5.4% | +24% | 12% | 10% |
; EV/Sales 2.6 vs. 2.0.
Growth vs. price
each dot a company · hover or tap for valuesSUPN and RGC and AMLX and PRGO and TRLV and BCRX and XERS have no P/E (earnings not positive) and are left out · hover or tap a dot for values.
Supernus Pharmaceuticals, Inc. — questions
- What is Supernus Pharmaceuticals, Inc.'s market cap?
- $2.4B.
- What is Supernus Pharmaceuticals, Inc.'s price-to-sales ratio?
- 2.9.
Every figure on this page comes from Supernus Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.